Omnicell (OMCL)
(Delayed Data from NSDQ)
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
Within Diabetes Care, Abbott (ABT) reports strong sales banking on growing demand for sensor-based continuous glucose monitoring system, FreeStyle Libre.
What's in Store for IDEXX Laboratories (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fourth-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued recovery in Clear Aligner shipment volumes in Q4.
Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's (HOLX) CE-Marked Fluent System Launched in Europe
by Zacks Equity Research
Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.
Phreesia (PHR) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Phreesia (PHR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Can Diagnostics Aid Hologic (HOLX) Q1 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the first quarter of fiscal 2021 amid the coronavirus-led economic doldrums.
What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.
Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.
Looking for a Growth Stock? 3 Reasons Why Omnicell (OMCL) is a Solid Choice
by Zacks Equity Research
Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
NextGen (NXGN) Solution Acts as Financial Bridge Amid COVID-19
by Zacks Equity Research
NextGen's (NXGN) cloud-based EHR platform, NextGen Office, enables specialty practices to improve their financial performance during the pandemic.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Omnicell (OMCL) Looks Good: Stock Adds 5% in Session
by Zacks Equity Research
Omnicell (OMCL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated
by Zacks Equity Research
Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.
Omnicell (OMCL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 20.00% and 2.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Down 7.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking
by Zacks Equity Research
Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.
Omnicell, Pharmaceutical Strategies Enter Acquisition Deal
by Zacks Equity Research
Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.
Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.
Omnicell (OMCL) Q2 Earnings Lag Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of -13.95% and 0.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?